ReviewMolecular therapy : the journal of the American Society of Gene Therapy2024
Mapping the cancer surface proteome in search of target antigens for immunotherapy.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Oncogenic Gαq Signaling Remodels the Tumor Surfaceome and Rewires Intracellular Networks in Uveal Melanoma Models.Cancers · 2026Article
- Extending structural surfaceomics to identify aberrant conformations of tumor surface proteins as potential immunotherapy targets.bioRxiv : the preprint server for biology · 2026Article
- EGFR-Targeted and MMP-Activated Membranolytic Peptides Kill Cancer Cells Specifically In Vitro and Reduce Tumor Growth In Vivo.Molecular pharmaceutics · 2026Article
- Establishing an RNA Sensor with High Sensitivity and Dynamic Range Utilizing a Signal Amplifier Platform.ACS synthetic biology · 2026Article
- Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance.Frontiers in immunology · 2026Review
- Genetically Engineered Cell Membrane-Coated Nanodrug for Targeted Treatment of Thyroid Cancer.Biomaterials research · 2026Article
- Proteomic Landscapes of 3D and 2D Models of High-Grade Serous Ovarian Carcinoma: Implications for Carboplatin Response.Journal of proteome research · 2025Article
- Establishing an RNA sensor with high sensitivity and dynamic range utilizing a signal amplifier platform.bioRxiv : the preprint server for biology · 2025Article
- Single-cell Analysis of Intracellular Transport and Expression of Cell Surface Proteins.bioRxiv : the preprint server for biology · 2025Article
- Review
- Challenges in the preclinical design and assessment of CAR-T cells.Frontiers in immunology · 2025Review
- Staying on target in gene and cell therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Immune-based therapeutic interventions recognizing proteins localized on the cell surface of cancer cells are emerging as a promising cancer treatment. Antibody-based therapies and engineered T cells are now approved by the Food and Drug Administration to treat some malignancies. These therapies utilize a few cell surface proteins highly expressed on cancer cells to release the negative regulation of immune activation that limits antitumor responses (e.g., PD-1, PD-L1, CTLA4) or to redirect the T cell specificity toward blood cancer cells (e.g., CD19 and B cell maturation antigen). One limitation preventing broader application of these novel therapeutic strategies to all cancer types is the lack of suitable target antigens for all indications owing in part to the challenges in identifying such targets. Ideal target antigens are cell surface proteins highly expressed on malignant cells and absent in healthy tissues. Technological advances in mass spectrometry, enrichment protocols, and computational tools for cell surface protein isolation and annotation have recently enabled comprehensive analyses of the cancer cell surface proteome, from which novel immunotherapeutic target antigens may emerge. Here, we review the most recent progress in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.